{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:39:22Z","timestamp":1790717962509,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.intimp.2025.114689","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:58:37Z","timestamp":1745063917000},"page":"114689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study"],"prefix":"10.1016","volume":"156","author":[{"given":"Mohannad O.","family":"Khrieba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar K.","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam Fathi","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar M.","family":"El-Haggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.114689_bb0005","doi-asserted-by":"crossref","first-page":"1434512","DOI":"10.3389\/fphar.2024.1434512","article-title":"The relation between Parkinson\u2019s disease and non-steroidal anti-inflammatories; a systematic review and meta-analysis","volume":"15","author":"Badawoud","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.114689_bb0010","article-title":"Calprotectin in parkinsonian disease: anticipation and dedication","volume":"102143","author":"Al-Kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2025.114689_bb0015","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18412","article-title":"Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease","volume":"28","author":"Alrouji","year":"2024","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0020","doi-asserted-by":"crossref","first-page":"9999146","DOI":"10.1155\/2021\/9999146","article-title":"Neuroinflammation: an integrating overview of reactive-Neuroimmune cell interactions in health and disease","volume":"2021","author":"K\u00f6lliker-Frers","year":"2021","journal-title":"Mediat. Inflamm."},{"issue":"18","key":"10.1016\/j.intimp.2025.114689_bb0025","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3390\/cells11182908","article-title":"Neuroinflammation and Parkinson\u2019s disease\u2014from neurodegeneration to therapeutic opportunities","volume":"11","author":"Ara\u00fajo","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.intimp.2025.114689_bb0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.intimp.2025.114689_bb0040","article-title":"Activated Protein Kinase: A New Target for Nutraceutical Compounds\/F. Mar\u00edn-Aguilar et al","volume":"18(2):288","author":"Monophosphate","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2025.114689_bb0045","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1172\/JCI67227","article-title":"AMPK, insulin resistance, and the metabolic syndrome","volume":"123","author":"Ruderman","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2025.114689_bb0050","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.intimp.2025.114689_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03114-4","article-title":"Activation of mTORC1 by LSECtin in macrophages directs intestinal repair in inflammatory bowel disease","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.intimp.2025.114689_bb0060","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.7150\/ijbs.29680","article-title":"Metformin inhibits the NLRP3 inflammasome via AMPK\/mTOR-dependent effects in diabetic cardiomyopathy","volume":"15","author":"Yang","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/JPD-171296","article-title":"Targeting AMPK signaling as a neuroprotective strategy in Parkinson\u2019s disease","volume":"8","author":"Curry","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12929-023-00961-z","article-title":"Neuroprotective effects of osmotin in Parkinson\u2019s disease-associated pathology via the AdipoR1\/MAPK\/AMPK\/mTOR signaling pathways","volume":"30","author":"Park","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2025.114689_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2017.08.013","article-title":"AMPK activation: role in the signaling pathways of neuroinflammation and neurodegeneration","volume":"298","author":"Peixoto","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.intimp.2025.114689_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.freeradbiomed.2024.02.023","article-title":"Neuroprotective effects of cordycepin on MPTP-induced Parkinson\u2019s disease mice via suppressing PI3K\/AKT\/mTOR and MAPK-mediated neuroinflammation","volume":"216","author":"Wang","year":"2024","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.114689_bb0085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.biopha.2008.01.017","article-title":"Glutathione and Parkinson\u2019s disease: is this the elephant in the room?","volume":"62","author":"Zeevalk","year":"2008","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5607\/en.2013.22.1.11","article-title":"Role of oxidative stress in Parkinson's disease","volume":"22","author":"Hwang","year":"2013","journal-title":"Experimental neurobiology."},{"key":"10.1016\/j.intimp.2025.114689_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112399","article-title":"Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine","volume":"145","author":"El-Haggar","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.114689_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtemb.2024.127474","article-title":"Reno-protective effect of nicorandil and pentoxifylline against potassium dichromate-induced acute renal injury via modulation p38MAPK\/Nrf2\/HO-1 and Notch1\/TLR4\/NF-\u03baB signaling pathways","volume":"85","author":"El-Shoura","year":"2024","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/SHK.0b013e3181cdc3e2","article-title":"Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways","volume":"34","author":"Kreth","year":"2010","journal-title":"Shock"},{"issue":"6","key":"10.1016\/j.intimp.2025.114689_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/ph17060681","article-title":"Activation of AMPK\/mTOR-driven autophagy and suppression of the HMGB1\/TLR4 pathway with Pentoxifylline attenuates doxorubicin-induced hepatic injury in rats","volume":"17","author":"Arab","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.intimp.2025.114689_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2025.114689_bb0120","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s11064-016-2129-0","article-title":"Pentoxifylline alleviates early brain injury after experimental subarachnoid hemorrhage in rats: possibly via inhibiting TLR 4\/NF-\u03baB signaling pathway","volume":"42","author":"Xia","year":"2017","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0125","article-title":"Pentoxifylline neuroprotective effects are possibly related to its anti-inflammatory and TNF-alpha inhibitory properties, in the 6-OHDA model of Parkinson\u2019s Disease","volume":"2015","author":"Neves","year":"2015","journal-title":"Parkinson\u2019s Disease."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/ijpvm.IJPVM_170_19","article-title":"Effect of pentoxifylline on apoptotic-related gene expression profile, learning and memory impairment induced by systemic lipopolysaccharide administration in the rat hippocampus","volume":"11","author":"Akbari","year":"2020","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.intimp.2025.114689_bb0135","series-title":"Research Article Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson\u2019s Disease","author":"Neves","year":"2025"},{"issue":"24","key":"10.1016\/j.intimp.2025.114689_bb0140","doi-asserted-by":"crossref","first-page":"25487","DOI":"10.18632\/aging.104155","article-title":"Pentoxifylline enhances antioxidative capability and promotes mitochondrial biogenesis for improving age-related behavioral deficits","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"10.1016\/j.intimp.2025.114689_bb0145","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.intimp.2025.114689_bb0150","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.10473","article-title":"The unified Parkinson\u2019s disease rating scale (UPDRS): status and recommendations","volume":"18","author":"Disease MDSTFoRSfPs.","year":"2003","journal-title":"Mov. Disord."},{"issue":"14","key":"10.1016\/j.intimp.2025.114689_bb0155","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2024.3101","article-title":"Does this patient have alcohol use disorder?: the rational clinical examination systematic review","volume":"331","author":"Wood","year":"2024","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17711\/SM.0185-3325.2015.012","article-title":"Psychometric and diagnostic properties of the drug abuse screening test (DAST): comparing the DAST-20 vs. the DAST-10","volume":"38","author":"Villalobos-Gallegos","year":"2015","journal-title":"Salud mental."},{"issue":"7","key":"10.1016\/j.intimp.2025.114689_bb0165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/000331978403500709","article-title":"Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs","volume":"35","author":"Strano","year":"1984","journal-title":"Angiology"},{"issue":"11","key":"10.1016\/j.intimp.2025.114689_bb0170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jash.2017.09.007","article-title":"Pentoxifylline treatment enhances antihypertensive activity of captopril through hemorheological improvement in spontaneously hypertensive rats during development of arterial hypertension","volume":"11","author":"Plotnikov","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"10.1016\/j.intimp.2025.114689_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson\u2019s disease: implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2025.114689_bb0180","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.ajem.2018.09.014","article-title":"Coronary artery bypass graft surgery complications: a review for emergency clinicians","volume":"36","author":"Montrief","year":"2018","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.intimp.2025.114689_bb0185","article-title":"Repurposing celecoxib as adjuvant therapy in patients with parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study","volume":"1-10","author":"Khrieba","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2025.114689_bb0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000492619","article-title":"The phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major depressive disorder patients: a proof-of-concept, randomized, double-blind, placebo-controlled trial","volume":"87","author":"El-Haggar","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.intimp.2025.114689_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.111047","article-title":"Efficacy of pentoxifylline for the treatment of bipolar I\/II patients with treatment-resistant depression: a proof-of-concept, randomized, double-blind, placebo-controlled trial","volume":"216","author":"Mohammad","year":"2024","journal-title":"Brain Res. Bull."},{"issue":"5","key":"10.1016\/j.intimp.2025.114689_bb0200","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1007\/s10787-024-01560-6","article-title":"Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6\/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study","volume":"32","author":"Bahaa","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"5","key":"10.1016\/j.intimp.2025.114689_bb0205","first-page":"345","article-title":"Pentoxifylline: a new agent for intermittent claudication","volume":"19","author":"McLeod","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.intimp.2025.114689_bb0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00228-011-1121-5","article-title":"The effect of different dosing regimens of levodopa\/carbidopa\/entacapone on plasma levodopa concentrations","volume":"68","author":"Ingman","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2025.114689_bb0215","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.29.12.1584","article-title":"Levodopa with benserazide or carbidopa in Parkinson disease","volume":"29","author":"Rinne","year":"1979","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0220","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson\u2019s disease severity levels and MDS-unified Parkinson\u2019s Disease rating scale","volume":"21","author":"Mart\u00ednez-Mart\u00edn","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.intimp.2025.114689_bb0225","first-page":"153","article-title":"Unified Parkinson\u2019s disease rating scale","author":"Fahn","year":"1987","journal-title":"Recent developments in Parkinson\u2019s disease."},{"issue":"7","key":"10.1016\/j.intimp.2025.114689_bb0230","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/s6070756","article-title":"Aspartate aminotransferase (AST\/GOT) and alanine aminotransferase (ALT\/GPT) detection techniques","volume":"6","author":"Huang","year":"2006","journal-title":"Sensors"},{"issue":"3","key":"10.1016\/j.intimp.2025.114689_bb0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/clinchem\/14.3.222","article-title":"Estimation of creatinine by the Jaffe reaction: a comparison of three methods","volume":"14","author":"Husdan","year":"1968","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2025.114689_bb0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12640-024-00716-0","article-title":"Blunted melatonin circadian rhythm in Parkinson\u2019s Disease: express bewilderment","volume":"42","author":"Turkistani","year":"2024","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.intimp.2025.114689_bb0245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fneur.2011.00068","article-title":"The promise of neuroprotective agents in Parkinson\u2019s disease","volume":"2","author":"Seidl","year":"2011","journal-title":"Front. Neurol."},{"key":"10.1016\/j.intimp.2025.114689_bb0250","article-title":"Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6\/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study","volume":"1-12","author":"Bahaa","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2025.114689_bb0255","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10157-021-02032-9","article-title":"A randomized double-blinded placebo-controlled clinical trial on protective effects of pentoxifylline on gentamicin nephrotoxicity in infectious patients","volume":"25","author":"Mousavinasab","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.intimp.2025.114689_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0237-4","article-title":"Transiently lowering tumor necrosis factor-\u03b1 synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice","volume":"12","author":"Baratz","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2025.114689_bb0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbr.2014.01.051","article-title":"Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions","volume":"264","author":"Machado-Filho","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"12","key":"10.1016\/j.intimp.2025.114689_bb0270","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/iub.1104","article-title":"Phosphodiesterases in neurodegenerative disorders","volume":"64","author":"Bollen","year":"2012","journal-title":"IUBMB Life"},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0275","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/clim.2000.4964","article-title":"The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo","volume":"98","author":"Beshay","year":"2001","journal-title":"Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.114689_bb0280","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.parkreldis.2013.04.006","article-title":"The effects of silent cerebral ischemic lesions on the prognosis of idiopathic Parkinson\u2019s disease","volume":"19","author":"Song","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.intimp.2025.114689_bb0285","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2008.12.064","article-title":"Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia","volume":"1260","author":"de Barros","year":"2009","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0306-3623(96)00314-X","article-title":"Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis","volume":"29","author":"Windmeier","year":"1997","journal-title":"Gen. Pharmacol. Vasc. S."},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0295","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.300.2.559","article-title":"Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-\u03b1) biosynthesis in alveolar epithelial cells","volume":"300","author":"Haddad","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2025.114689_bb0300","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1172\/JCI11003","article-title":"Brain tissue responses to ischemia","volume":"106","author":"Lee","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.intimp.2025.114689_bb0305","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0928-0987(99)00017-2","article-title":"Alterations of second messenger systems in the rat brain after 6-hydroxydopamine lesions of the medial forebrain bundle","volume":"8","author":"Araki","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.114689_bb0310","first-page":"511","article-title":"Mesencephalic ischemia and Parkinson's disease","volume":"75","author":"Rafael","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1081\/JDI-42728","article-title":"Comparative analysis of the renoprotective effects of pentoxifylline and vitamin E on streptozotocin-induced diabetes mellitus","volume":"27","author":"Davila-Esqueda","year":"2005","journal-title":"Ren. Fail."},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0320","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003246-199402000-00019","article-title":"Effects of pentoxifylline on cerebral blood flow, metabolism, and evoked response after total cerebral ischemia in dogs","volume":"22","author":"ToUNG","year":"1994","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.intimp.2025.114689_bb0325","first-page":"181","article-title":"The effect of Pentoxifylline on IL-1beta and TNF-alpha mRNA gene expression in hypoxic-ischemic brain injury of immature rat. Journal of the Korean child neurology","author":"Kim","year":"1999","journal-title":"Society"},{"issue":"3","key":"10.1016\/j.intimp.2025.114689_bb0330","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/nu13030803","article-title":"Methylxanthines and neurodegenerative diseases: an update","volume":"13","author":"Janitschke","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2025.114689_bb0335","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lfs.2018.05.048","article-title":"Targeting Keap-1\/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis","volume":"207","author":"Ali","year":"2018","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0340","article-title":"The effects of quinacrine, proglumide, and pentoxifylline on seizure activity, cognitive deficit, and oxidative stress in rat lithium-pilocarpine model of status epilepticus","volume":"2014","author":"Ahmad","year":"2014","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2025.114689_bb0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejphar.2011.04.030","article-title":"The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis","volume":"662","author":"Peterson","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2025.114689_bb0350","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2007.12.004","article-title":"Pentoxifylline ameliorates lithium-pilocarpine induced status epilepticus in young rats","volume":"12","author":"Tariq","year":"2008","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.intimp.2025.114689_bb0355","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fnins.2018.00628","article-title":"HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction","volume":"12","author":"Paudel","year":"2018","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.intimp.2025.114689_bb0360","first-page":"427","article-title":"Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines","volume":"34","author":"Ji","year":"2004","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.intimp.2025.114689_bb0365","series-title":"Pentoxifylline Treatment Alleviates Kidney Ischemia\/Reperfusion Injury: Novel Involvement of Galectin-3 and ASK-1\/JNK & ERK1\/2\/NF-kB\/HMGB-1 Trajectories","author":"Abdallah","year":"2021"},{"key":"10.1016\/j.intimp.2025.114689_bb0370","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.30.1_supplement.633.9","article-title":"Pentoxifylline modulates the AKT\/mTOR\/AMPK pathway: potential role as an adjunct in cancer chemotherapy","volume":"30","author":"Le","year":"2016","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0375","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jnr.23144","article-title":"Pentoxifylline and propentofylline prevent proliferation and activation of the mammalian target of rapamycin and mitogen activated protein kinase in cultured spinal astrocytes","volume":"91","author":"Norsted Gregory","year":"2013","journal-title":"J. Neurosci. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.114689_bb0380","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.radonc.2012.08.023","article-title":"Radiation-induced enteropathy: molecular basis of pentoxifylline\u2013vitamin E anti-fibrotic effect involved TGF-\u03b21 cascade inhibition","volume":"105","author":"Hamama","year":"2012","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.intimp.2025.114689_bb0385","series-title":"editor Regulation of renal potassium secretion: molecular mechanisms. Seminars in nephrology","author":"Welling","year":"2013"},{"key":"10.1016\/j.intimp.2025.114689_bb0390","article-title":"Immunomodulatory effects of Pentoxifylline: profiling data based on RAW 264.7 cellular signaling","volume":"11(17):8273","author":"Seo","year":"2021","journal-title":"Appl. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2025.114689_bb0395","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/antiox9070597","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"9","author":"Chang","year":"2020","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.intimp.2025.114689_bb0400","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/antiox12040955","article-title":"Oxidative stress and neuroinflammation in Parkinson\u2019s disease: the role of dopamine oxidation products","volume":"12","author":"Chakrabarti","year":"2023","journal-title":"Antioxidants"},{"issue":"8","key":"10.1016\/j.intimp.2025.114689_bb0405","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/1440-1681.13508","article-title":"Pentoxifylline prevents epileptic seizure via modulating HMGB1\/RAGE\/TLR4 signalling pathway and improves memory in pentylenetetrazol kindling rats","volume":"48","author":"Badawi","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0410","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1472-8206.2001.00007.x","article-title":"The effect of pentoxifylline on intestinal ischemia\/reperfusion injury","volume":"15","author":"\u015eener","year":"2001","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.114689_bb0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jphs.2021.10.004","article-title":"Dopamine inhibits the expression of proinflammatory cytokines of microglial cells through the formation of dopamine quinone in the mouse striatum","volume":"148","author":"Yoshioka","year":"2022","journal-title":"J. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2025.114689_bb0420","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2460\/ajvr.80.7.702","article-title":"Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite after intravenous administration of increasing doses to sheep","volume":"80","author":"Corum","year":"2019","journal-title":"Am. J. Vet. Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.114689_bb0425","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/15347346211050769","article-title":"Efficacy and safety of pentoxifylline for venous leg ulcers: an updated meta-analysis","volume":"23","author":"Sun","year":"2024","journal-title":"Int J Low Extrem Wounds"},{"issue":"8","key":"10.1016\/j.intimp.2025.114689_bb0430","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/jir.2005.25.485","article-title":"Immunomodulatory effects of IFN-\u03b21a treatment alone or associated with Pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS)","volume":"25","author":"Pede","year":"2005","journal-title":"J. Interf. Cytokine Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.114689_bb0435","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/YIC.0000000000000353","article-title":"Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial","volume":"36","author":"Farajollahi-Moghadam","year":"2021","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.114689_bb0440","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/jcpt.13565","article-title":"Pentoxifylline in the treatment of neonatal vasospasm and thromboembolism: an observational case series study","volume":"47","author":"Bayraktar","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.intimp.2025.114689_bb0445","article-title":"Efficacy, safety and mechanistic insights of pentoxifylline in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"1-14","author":"Kassar","year":"2025","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"04","key":"10.1016\/j.intimp.2025.114689_bb0450","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/a-2291-7204","article-title":"Pentoxifylline as a novel add-on therapy for major depressive disorder in adult patients: a randomized, double-blind, placebo-controlled trial","volume":"57","author":"Mohammad","year":"2024","journal-title":"Pharmacopsychiatry"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925006794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:47:24Z","timestamp":1762552044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925006794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":90,"alternative-id":["S1567576925006794"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114689","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.114689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114689"}}